Aardvark Therapeutics (AARD) vs CervoMed (CRVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CervoMed (CRVO) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 83.6% versus a loss of 90.2%. CervoMed is the larger company by market cap ($22.1 million vs $20.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | CRVO |
|---|---|---|
| Share price | $0.9226 | $1.46 |
| Market cap | $20.20M | $22.09M |
| 1-day change | -7.74% | +9.77% |
| YTD return | -92.97% | -81.52% |
| 1-year return | -90.15% | -83.56% |
| 5-year return | — | -95.01% |
| EPS (TTM) | $-3.33 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $4.01M |
| Revenue growth (YoY) | — | -58.86% |
| Net income (latest FY) | $-57.59M | $-26.97M |
| Operating margin | — | -706.22% |
| Net margin | — | -673.06% |
| 52-week high | $16.60 | $10.00 |
| 52-week low | $0.90 | $1.27 |
| Distance from 52-week high | -94.44% | -85.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1104.21% | +954.79% |
| Average volume | 643.53K | 489.10K |
| Shares outstanding | 21.89M | 15.13M |
| Employees | 28 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
AARD vs CRVO FAQ
Which is bigger, Aardvark Therapeutics or CervoMed?
CervoMed (CRVO) is larger, with a market capitalization of $22.09M compared with $20.20M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or CRVO?
CRVO returned -83.56% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and CervoMed in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.